Zelira Therapeutics Balance Sheet Health
Financial Health criteria checks 2/6
Zelira Therapeutics has a total shareholder equity of A$-4.2M and total debt of A$5.7M, which brings its debt-to-equity ratio to -135.5%. Its total assets and total liabilities are A$5.2M and A$9.4M respectively.
Key information
-135.5%
Debt to equity ratio
AU$5.65m
Debt
| Interest coverage ratio | n/a |
| Cash | AU$586.16k |
| Equity | -AU$4.17m |
| Total liabilities | AU$9.36m |
| Total assets | AU$5.18m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: G1G has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: G1G has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: G1G has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: G1G's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: G1G has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: G1G is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.